Immunotherapy treatments approved for stage II non-small cell lung cancer
If you have stage II lung cancer that is treatable by surgery, you may receive immunotherapy and chemotherapy prior to your surgery. This is called neoadjuvant treatment and is meant to increase the efficacy of the surgery.
APPROVED THERAPY:
- Opdivo (nivolumab, a PD-1 Inhibitor) – approved in combination with chemotherapy for stage II NSCLC patients whose cancer can be removed by surgery.
- Tecentriq (atezolizumab, a PD-L1 Inhibitor) – approved after adjuvant chemotherapy for stage II NSCLC patients with >1% PD-L1 whose cancer can be removed by surgery.